[
  {
    "title": "Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications",
    "url": "https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 67% of patients completed assessments, reducing discontinuation risk by 30%."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Integrate AI-driven reminders to optimize patient engagement and completion rates."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Increasing demand for PRO data in oncology trials to meet regulatory standards."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Self-selection bias may skew results toward healthier patients, affecting clinical validity."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: EQ-5D-5 L and MLHFQ predict all-cause mortality and HF-related hospitalization in ATTR-CM."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [ROADMAP]**: Develop ePRO platforms with adaptive questionnaires to capture PROs efficiently."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: FDA prioritizing PRO data for accelerated approval of rare diseases like ATTR-CM."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Baseline differences between trial populations may limit direct comparison of PRO outcomes."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Symptom Assessment and Early Chemotherapy Discontinuation in ... - medRxiv",
    "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337194v1",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: 67% of GI cancer patients completed assessments, lowering early discontinuation risk by ~30%, with consistent results across prognostic groups."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN [SHIP NOW]**: Automate day-3 reminders to improve symptom assessment completion rates among patients."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: FDA now mandates PRO data in trials within 12 months, emphasizing clinical validity of patient-reported outcomes."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Study limited by self-selection bias; healthier patients may complete assessments more frequently."
      }
    ],
    "model": "granite4:tiny-h"
  }
]